17 completed, 4 terminated, 3 unknown, 1 recruiting. 26 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 17, Terminated 4, Unknown 3, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Caspofungin: new trials by email Literature Review of Caspofungin trials Research Report on Caspofungin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia Caspofungin Acetate 50 MG, Physiologic saline - Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection | Phase 1 / Phase 2 | Recruiting | University Hospital, Tours | 100 | 2025-12-02 | 2026-10-09 |
| A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis HRS9432, Caspofungin Acetate for Injection - Patients With Candidemia and/or Invasive Candidiasis | Phase 2 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 61 | 2024-04-27 | 2026-09-10 |
| Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin Caspofungin - Fungal Infection | Phase 2 | Completed | Cttq | 32 | 2018-09-17 | 2021-07-07 |
| Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients F901318, Caspofungin - Pulmonary Aspergillosis - Invasive, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | F2G Ltd | 2017-04-20 | 2018-02-15 | |
| CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension CD101, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 207 | 2016-07-26 | 2020-12-08 |
| Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064) Caspofungin, Amphotericin B Deoxycholate - Candidiasis, Invasive | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 51 | 2014-01-15 | 2019-11-25 |
| the Influence of Prophylactic and Empirical Anti-fungal Treatment in Severe Sepsis Patients With Perforations fluconazole and caspofungin - Intra-abdominal Perforation | Phase 2 | Completed | Nanjing PLA General Hospital | 223 | 2012-03-01 | 2016-10-21 |
| Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection Caspofugin based combination therapy - Leukemia, Transplantation, Hematopoietic Stem Cell | Phase 2 | Unknown | Shanghai Jiao Tong University School of Medicine | 55 | 2011-12-01 | 2016-05-10 |
| Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis caspofungin - Fungal Infection | Phase 2 | Completed | Werner J. Heinz | 25 | 2011-04-01 | 2014-01-09 |
| Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067) Caspofungin acetate, Placebo - Invasive Candidiasis | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 15 | 2010-12-01 | 2017-03-24 |
| A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074) Caspofungin - Candidiasis, Esophageal, Candidiasis, Invasive | Phase 2 | Completed | Merck Sharp & Dohme LLC | 20 | 2010-07-06 | 2018-08-27 |
| Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients Caspofungin - Fungemia, Mycoses | Phase 2 | Unknown | Azienda Ospedaliera di Padova | 38 | 2009-05-01 | 2012-07-18 |
| Pharmacokinetics of Caspofungin in Burn Patients Caspofungin (drug) - Thermal Injury | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 2 | 2009-02-01 | 2026-03-04 |
| Prophylaxis of Fungal Invasive Infections in Leukemia Caspofungin - Invasive Pulmonary Aspergillosis | Phase 2 | Completed | Northern Italy Leukemia Group | 100 | 2007-01-01 | 2009-09-22 |
| Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis caspofungin - Invasive Aspergillosis | Phase 2 | Completed | University of Cologne | 46 | 2006-10-01 | 2013-07-31 |
| Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058) caspofungin acetate - Candidiasis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 16 | 2006-05-01 | 2017-02-23 |
| Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant caspofungin acetate - Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 171 | 2005-02-01 | 2012-09-24 |
| A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation caspofungin, liposomal amphotericin B - Hematopoietic Stem Cell Transplantation, Fungus Diseases | Phase 2 | Completed | University Hospital Muenster | 75 | 2004-05-01 | 2008-01-16 |
| Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042) caspofungin acetate - Fungal Infection | Phase 2 | Completed | Merck Sharp & Dohme LLC | 16 | 2004-05-01 | 2017-02-23 |
| Caspofungin for the Treatment of Non-blood Candida Infections (0991-045) MK0991, caspofungin acetate/Duration of Treatment: variable - Candidiasis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 48 | 2004-05-01 | 2017-02-23 |
Showing 20 of 26. Sign in to see all of them.
Mycoses (10) · Aspergillosis (5) · Candidiasis (5) · Candidiasis, Invasive (4) · Fungemia (2) · Infections (2) · Invasive Fungal Infections (2) · Invasive Pulmonary Aspergillosis (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · AIDS-Related Opportunistic Infections (1) · Ataxia Telangiectasia (1) · Blast Crisis (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1)
Merck Sharp & Dohme LLC (10) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Ospedaliera di Padova (1) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Cttq (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · F2G Ltd (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Grupo de Estudio de Infecciones en Transplantados (1) · Nanjing PLA General Hospital (1) · Northern Italy Leukemia Group (1) · OHSU Knight Cancer Institute (1) · Shanghai Jiao Tong University School of Medicine (1) · University Hospital Muenster (1) · University Hospital, Tours (1)
Germany (4) · Italy (4) · Belgium (3) · China (3) · France (3) · United States (3) · Spain (2) · Bulgaria (1) · Canada (1) · Greece (1) · Hungary (1) · Romania (1) · Russia (1) · Slovakia (1) · Switzerland (1)
Andreas Groll, M.D. (1) · Chiara Cattaneo (1) · Christophe Vinsonneau, MD (1) · Claudio Viscoli, MD (1) · Daniele Neri, MD (1) · Giuseppe Rossi, MD (1) · Jesus Fortun, MD (1) · Jianda Hu, Ph.D (1) · Ling Wang, M.D. (1) · Lynne Strasfeld, MD (1) · Oliver A. Cornely, MD (1)
PMID 16304338, PMID 16505648, PMID 18046534, PMID 19172247, PMID 19841031, PMID 20431381, PMID 20946413, PMID 21729932, PMID 21911573, PMID 22548840, PMID 22585216, PMID 23335740, PMID 23940606, PMID 25701307, PMID 26935726, PMID 30776290, PMID 31548210, PMID 31586424, PMID 31633150, PMID 32194238, PMID 32955088, PMID 38008099, PMID 38502709, PMID 39468640, PMID 39529079, PMID 41151592, PMID 41940006, PMID 9872631
2008 (1), 2009 (1), 2015 (1), 2023 (1)